Pfizer (PFE), BioTech (BNTX) Report Complete Patient Dosing in First Cohort of Ph. 1/2 Trial of COVID-19 vaccine candidates in Germany

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. ABBV
2. MU
3. SPCX
4. IBM
5. ACN
6. NVDA
7. PRIM
8. META
9. SPY
10. TSLA

Go back to Pfizer (PFE), BioTech (BNTX) Report Complete Patient Dosing in First Cohort of Ph. 1/2 Trial of COVID-19 vaccine candidates in Germany

BioNTech and Pfizer announce completion of dosing for first cohort of Phase 1/2 trial of COVID-19 vaccine candidates in Germany

April 29, 2020 3:43 AM EDT

MAINZ, Germany and NEW YORK, April 29, 2020 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, BioNTech or the Company) and Pfizer Inc. (NYSE: PFE) have announced that the first cohort of BioNTechs Phase 1/2 clinical trial has been dosed. Twelve study participants were dosed with vaccine candidate BNT162 in Germany since dosing began on April 23, 2020. The trial is the first clinical trial of a COVID-19 vaccine candidate in Germany. Pfizer and BioNTech plan to initiate trials for BNT162 in the United States upon regulatory approval, which is expected shortly.

The dose escalation portion... More